Original Article
Loss of BAP1 expression is a very rare event in gastrointestinal stromal tumors

Hee Jung Kwon, Joon Hyuk Choi, Mi Jin Gu

Department of Pathology, Yeungnam University College of Medicine, Daegu, South Korea

Received April 19, 2017; Accepted September 4, 2017; Epub September 15, 2017; Published September 30, 2017

Abstract: Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors affecting the gastrointestinal tract, are primarily driven by activating KIT and platelet-derived growth factor receptor alpha (PDGFRα) mutations and respond to targeted tyrosine kinase therapy. However, GISTs exhibit various clinical behaviors, regardless of the proposed risk classification. Here, we investigated the expression of BRCA1-associated protein-1 (BAP1) in GIST and analyzed its prognostic significance and utility as a marker in the context of differential diagnosis. Among a total of 226 GIST, only one (0.44%, 1/226 cases) GIST exhibited a loss of BAP1 expression. In the univariate analysis, small intestinal and colorectal GISTs, GISTs with necrosis, recurrence/metastasis, or a higher risk of malignancy were associated with poor overall survival. In the multivariate analysis, GISTs with a higher risk of malignancy or recurrence/metastasis were identified as independent prognostic factors. We conclude that a loss of BAP1 expression is a very rare event, then BAP1 would not play a major role in pathogenesis of GIST.

Keywords: Gastrointestinal stromal tumor, BAP1, BRCA1-associated protein, immunohistochemistry

Introduction
Gastrointestinal stromal tumors (GISTs) comprise the most common type of mesenchymal-neoplasms of the gastrointestinal tract. These tumors are resistant to conventional chemotherapy and radiotherapy [1, 2]. In adults, the majority of GISTs harbor characteristic oncogenic mutations in KIT (80-85%) and PDGFRα (5-7%) and respond to targeted tyrosine kinase (TK) therapy [2, 3]. However, approximately 10-15% of GISTs are KIT/PDGFRα wild-type (WT) and are less sensitive to TK inhibitors (TKI).

BRCA1-associated protein-1 (BAP1) is a deubiquitinating enzyme that plays important roles in chromatin modulation, DNA transcription and cell cycle regulation, cellular growth, and DNA repair [3-5]. BAP1 is now recognized as a tumor suppressor gene, and germline BAP1 mutations have been associated with autosomal dominant cancer syndromes that include cutaneous and uveal melanoma, renal cell carcinoma, cutaneous basal cell carcinoma, and malignant mesothelioma [6]. Somatic BAP1 mutations have also been investigated in the context of mesothelioma, intrahepatic cholangiocarcinoma (ICC), clear cell renal cell carcinoma, and atypical cutaneous spitzoid tumors [3, 6-9]. Immunohistochemistry (IHC) for BAP1 appears to serve as a reliable and highly sensitive/specific marker of BAP1 mutation or inactivation, irrespective of underlying genetic alterations [4, 7, 10]. Accordingly, the BAP1 expression status has been described as clinically significant in a variety of human tumors [6, 9, 11-13].

The present study aimed to investigate the BAP1 expression statuses of GISTs, to assess the clinical and pathological significance, and to identify the utility in differential diagnosis from other tumors. To the best of our knowledge, BAP1 expression status has not previously been assessed in GIST.

Materials and methods

Patient characteristics

Between 1997 and 2016, a total of 226 GISTs from the stomach (154 cases), small intestine (67 cases), colon and rectum (3 cases), and extra gastrointestinal locations (pelvic cavity and abdominal cavity) were included. Medical
BAP1 expression in GIST

Table 1. Clinicopathologic features of GISTs

<table>
<thead>
<tr>
<th>Clinicopathologic factors</th>
<th>Number (%)</th>
<th>Death* (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>M:F</td>
<td>120 (53.1):106 (46.9)</td>
<td>20 (10.8):13 (7.0)</td>
</tr>
<tr>
<td>Location</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stomach</td>
<td>154 (68.1)</td>
<td>15 (12.3)</td>
</tr>
<tr>
<td>Small intestine</td>
<td>67 (29.6)</td>
<td>16 (11.6)</td>
</tr>
<tr>
<td>Colon and rectum</td>
<td>3 (1.3)</td>
<td>2 (1.1)</td>
</tr>
<tr>
<td>Others</td>
<td>2 (0.9)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Cell type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spindle</td>
<td>206 (91.1)</td>
<td>30 (16.2)</td>
</tr>
<tr>
<td>Epithelioid</td>
<td>9 (4.0)</td>
<td>2 (1.1)</td>
</tr>
<tr>
<td>Mixed</td>
<td>11 (4.9)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Risk of malignancy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>26 (11.5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Very low</td>
<td>69 (30.5)</td>
<td>2 (1.1)</td>
</tr>
<tr>
<td>Low</td>
<td>45 (19.9)</td>
<td>2 (1.1)</td>
</tr>
<tr>
<td>Moderate</td>
<td>40 (17.7)</td>
<td>7 (3.8)</td>
</tr>
<tr>
<td>High</td>
<td>46 (20.4)</td>
<td>22 (11.9)</td>
</tr>
<tr>
<td>Mucosal invasion</td>
<td>25 (11.1)</td>
<td>6 (3.2)</td>
</tr>
<tr>
<td>Necrosis</td>
<td>37 (16.4)</td>
<td>13 (7.0)</td>
</tr>
<tr>
<td>Recurrence or metastasis</td>
<td>26 (11.5)</td>
<td>18 (9.7)</td>
</tr>
<tr>
<td>CD117 positive</td>
<td>222 (98.2)</td>
<td>33 (17.8)</td>
</tr>
<tr>
<td>DOG1 positive</td>
<td>222 (98.2)</td>
<td>32 (17.3)</td>
</tr>
<tr>
<td>BAP1 loss</td>
<td>1 (0.44)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

*Available follow-up: 185 cases.

records were reviewed to determine each patient’s age, sex, most recent follow-up visit, survival status, and the presence or absence of GIST-related disease. The following clinicopathologic characteristics were also assessed: tumor location, tumor size, mitotic count, tumor cell type, necrosis, mucosal ulceration, and recurrence or metastasis. The risk of malignant behavior was classified according to the system proposed by the National Comprehensive Cancer Network (NCCN) Guideline [14], and further classified as low, moderate, or high risk (Table 1). Overall survival (OS) was defined as the time from surgical resection to death or the last follow-up. The follow-up period ended in October 2016 (OS range: 0-215 months) and we could get follow-up data from 185 patients. Patients with a higher risk malignant behavior or metastasis received imatinib therapy. This study was approved by our institutional Human Ethics Review Board.

Tissue microarray block construction

We obtained two to five 2-mm cores from the most representative tumor area of each case, and arrayed in a tissue microarray (TMA) block. One core from breast carcinoma, thyroid papillary carcinoma, normal gastric mucosa, palatine tonsil, or uterine leiomyoma was obtained and arrayed in a TMA block, and used as control tissues. We made total 11 TMA blocks with 226 cases.

Immunohistochemistry

Immunohistochemistry for BAP1 was performed on an automated Benchmark® platform (Ventana Medical Systems, Tucson, AZ, USA). For BAP1, a mouse monoclonal antibody (clone C-4, Santa Cruz Biotechnology, Dallas, TX, USA) was used at a 1:100 dilution after onboard heat-induced epitope retrieval in a high-pH CC1 buffer (99°C, 1 h). Staining was visualized using the UltraView™ universal DAB detection kit (Automated BenchMark®, Ventana), which included a hydrogen peroxide substrate and a 3,3’-diaminobenzidine chromogen solution. The slides were subsequently counterstained with hematoxylin.

Interpretation of IHC

The slides were assessed by an investigator who was blinded to the patients’ clinicopathologic information. We defined a loss of BAP1 expression as a complete absence of nuclear staining in tumor cells. Lymphocytes and background stromal cells served as the positive controls.

Statistical analyses

The chi-square test and Fisher’s exact test were used to examine correlations between categorical variables. Overall survival was defined as described above. Disease-free survival (DFS) was defined as the postoperative interval without a known recurrence or metastasis. Survival rates were calculated using the Kaplan-Meier method. Associations between survival rates and various clinicopathologic factors were evaluated using the log-rank test. A Cox proportional hazard regression model was used to evalu-
BRCA1-associated protein-1 (BAP1) expression in GIST

**Results**

**Clinicopathologic characteristics**

One hundred twenty-six male and 120 female patients with a median age of 58.5 years (range: 22-88 years) were included in this study. The median tumor size was 4.79 cm (range: 1-23 cm). CD117 and DOG1 expression were detected in 222 cases (98.2%), respectively.
SDHB negativity was observed only in two wild-type gastric GISTs in a 56-year-old female and 15-year-old male patient. These SDHB-negative GISTs exhibited diffuse strong positive CD117 and DOG1 staining.

Immunohistochemistry of BAP1 and its clinical significance

Of the 226 GISTs, only one case (0.44%) exhibited a loss of BAP1 expression (Figure 1A). All other cases exhibited diffuse homogeneous BAP1 positivity (Figure 1B). We next stained a whole section from a representative tumor block to confirm the loss of BAP1 expression, and observed that the tumor cells were completely negative for BAP1. Statistically, we observed no significance associations between loss of BAP1 expression and clinicopathologic factors. In univariate analysis, small intestinal and colorectal GISTs, GISTs with necrosis, recurrence/metastasis, or a higher risk of malignancy were significantly associated with a poor OS and DFS. In a multivariate analysis, GISTs with a higher risk of malignancy and recurrence/metastasis were confirmed as independent prognostic factors (Tables 2, 3).

Discussion

In a study of 226 GIST cases, a loss of BAP1 expression was observed in only one small intestinal GIST. The indicated patient was a 33-years-old man without a family or personal history of BAP1-associated malignancy. The tumor was a 9 cm × 5.5 cm-sized mass with mucosal ulceration, 1/50 high-powered field mitosis rate, spindle cell histology, diffuse strong CD117 and DOG1 positivity, and KIT mutation. Irrespective of imatinib therapy, the tumor metastasized to abdominal wall (12 months later) and brain (90 months later), but no other malignancy was not detected for follow-up period. Recently, germline mutation in BAP1 have been reported in causing a hereditary tumor syndrome that gives an increased risk of cancers [15]. Although we did not perform BAP1 germline mutation test for this case, he was unlikely BAP1-associated hereditary syndrome because he did not have BAP1-related family history or BAP1-associated malignancy.

Studies of BAP1 expression have increased since the first report of the diagnostic utility of this marker for mesothelial lesions. A loss of BAP1 expression was found to be 100% specific for malignant mesothelioma and could be used to distinguish malignant mesothelioma from benign mesothelial proliferation [9, 16]. However, studies to determine the clinical significance of BAP1 expression in several human tumors has yielded varied results. A meta-analysis of BAP1 expression in cancers revealed that 1) BAP1 is generally a poor prognostic marker for cancers, except mesothelioma; 2) BAP1 mutations are associated with high-grade colorectal and renal cell carcinomas; and 3) BAP1-mutated cancers more commonly occur in women than in men [6]. In contrast, mesotheliomas with loss of BAP1 expression showed a better outcome compared to those with BAP1 expression, and this association was notable among epithelioid cases [13]. In lung cancer, Fan observed a 52.5% rate of BAP1 loss among advanced cases, and this loss was associated with lymph node metastasis and poor OS [17]. However, two other studies identified a loss of BAP1 expression in only one case of primary non-small cell lung cancer (1/101 and 1/257 cases), and suggested that BAP1 could be used to distinguish primary lung carcinoma from malignant mesothelioma [13, 18, 19]. In gastric carcinoma, decreased BAP1 expression was associated with a higher histologic grade, TNM stage, metastasis, and reduced OS [20]. Similarly, in clear cell renal cell carcinoma, a loss of BAP1 was associated with a larger tumor size, higher TNM stage, higher nuclear grade, metastasis, and reduced OS [12, 21]. In two studies of intrahepatic cholangiocarcinoma (ICC), Misumi observed that a loss of BAP1, an independent prognostic factor, was associated with mass-forming small duct type ICC, reduced perineural invasion and mucin production [22]. In cholangiocarcinoma, BAP1 mutation was found to be correlate with aggressive disease and poor responses to standard therapies [23]. However, recent studies have revealed rare losses of BAP1 in lung and other human cancers. A loss of BAP1 expression was observed in only one of 306 cases of pancreatic ductal adenocarcinoma, despite the close anatomical proximity and similarities of this type of cancer (e.g., aspects of embryogenesis) with the bile duct [24]. These findings suggest that a loss of BAP1 expression could be used to distinguish a diagnosis of pancreatic ductal adenocarcinoma from ICC. Furthermore, a loss of BAP1 expression was very rare among peritoneal and
gynecological serous adenocarcinomas and could facilitate a differential diagnosis of abdominal mesothelioma [13].

A loss of BAP1 expression has shown to be 100% specific for malignancy. However, Hwang observed that losses of BAP1 were observed in 15% of sarcomatous/desmoplastic mesotheliomas. In contrast, no BAP1 loss was observed in sarcomatoid carcinoma [25]. These findings and our study results suggest that BAP1 loss might not assist a differential diagnosis in a small biopsy that includes KIT (-) GIST, sarcomatoid carcinoma, and sarcomatoid/desmoplastic mesothelioma. The germline and somatic mutation of BAP1 is considered uncommon event in GIST, since most BAP1 mutation is highly associated with loss of protein expression.

In summary, we conducted the first study of BAP1 expression status in a large cohort of GISTs. The loss of BAP1 expression was observed in only one case, and it suggests that BAP1 expression loss is a very rare event in GIST and BAP1 would not play a major role in pathogenesis of GIST. The risk of malignancy and recurrence/metastasis were confirmed as independent prognostic factors for GIST.

Acknowledgements

This work was supported by the 2016 Yeungnam University Research Grant.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Mi Jin Gu, Department of Pathology, Yeungnam University College of Medicine, 170 Hyeonchung-ro, Nam-gu, Daegu 42415, South Korea. Tel: 82-53-640-6756; Fax: 82-53-622-8432; E-mail: mjgu@yu.ac.kr

References


